Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 738

1.

TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.

Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V.

J Clin Oncol. 2019 Feb 5:JCO2018787986. doi: 10.1200/JCO.2018.78.7986. [Epub ahead of print]

PMID:
30721110
2.

Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study.

Williams LA, Casbas-Hernandez P, Nichols HB, Tse CK, Allott EH, Carey LA, Olshan AF, Troester MA.

PLoS One. 2019 Jan 25;14(1):e0211488. doi: 10.1371/journal.pone.0211488. eCollection 2019.

3.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Jan 18. pii: blood-2018-10-881961. doi: 10.1182/blood-2018-10-881961. [Epub ahead of print]

PMID:
30658992
4.

An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer.

Gogate A, Rotter JS, Trogdon JG, Meng K, Baggett CD, Reeder-Hayes KE, Wheeler SB.

Breast Cancer Res Treat. 2019 Jan 2. doi: 10.1007/s10549-018-05099-3. [Epub ahead of print] Review.

PMID:
30603995
5.

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE.

Cancer. 2019 Feb 15;125(4):533-540. doi: 10.1002/cncr.31817. Epub 2018 Dec 20.

PMID:
30570744
6.

Mastectomy May Be an Inferior Oncologic Approach Compared to Breast Preservation.

Marks LB, Gupta GP, Muss HB, Ollila DW.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):78-80. doi: 10.1016/j.ijrobp.2018.07.2021. Epub 2018 Dec 12. No abstract available.

PMID:
30563667
7.

Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis.

Nishijima TF, Shachar SS, Muss HB, Tamura K.

Oncologist. 2018 Dec 14. pii: theoncologist.2018-0449. doi: 10.1634/theoncologist.2018-0449. [Epub ahead of print]

PMID:
30552160
8.

Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.

Nyrop KA, Deal AM, Shachar SS, Basch E, Reeve BB, Choi SK, Lee JT, Wood WA, Anders CK, Carey LA, Dees EC, Jolly TA, Reeder-Hayes KE, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Muss HB.

Oncologist. 2018 Dec 14. pii: theoncologist.2018-0590. doi: 10.1634/theoncologist.2018-0590. [Epub ahead of print]

PMID:
30552158
9.

Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ.

Kumar S, Lindsay D, Chen QB, Garrett AL, Tan XM, Anders CK, Carey LA, Gupta GP.

NPJ Breast Cancer. 2018 Dec 5;4:39. doi: 10.1038/s41523-018-0093-3. eCollection 2018.

10.

Macrophage cells secrete factors including LRP1 that orchestrate the rejuvenation of bone repair in mice.

Vi L, Baht GS, Soderblom EJ, Whetstone H, Wei Q, Furman B, Puviindran V, Nadesan P, Foster M, Poon R, White JP, Yahara Y, Ng A, Barrientos T, Grynpas M, Mosely MA, Alman BA.

Nat Commun. 2018 Dec 5;9(1):5191. doi: 10.1038/s41467-018-07666-0.

11.

Frailty and health-related quality of life in older women with breast cancer.

Williams GR, Deal AM, Sanoff HK, Nyrop KA, Guerard EJ, Pergolotti M, Shachar SS, Reeve BB, Bensen JT, Choi SK, Muss HB.

Support Care Cancer. 2018 Nov 27. doi: 10.1007/s00520-018-4558-6. [Epub ahead of print]

PMID:
30484012
12.

Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101.

Barginear M, Dueck AC, Allred JB, Bunnell C, Cohen HJ, Freedman RA, Hurria A, Kimmick G, Le-Rademacher JG, Lichtman S, Muss HB, Shulman LN, Sitiki Copur M, Biggs D, Ramaswamy B, Lafky JM, Jatoi A.

Oncologist. 2018 Nov 8. pii: theoncologist.2018-0298. doi: 10.1634/theoncologist.2018-0298. [Epub ahead of print]

PMID:
30409792
13.

An assessment of prognostic immunity markers in breast cancer.

Yang B, Chou J, Tao Y, Wu D, Wu X, Li X, Li Y, Chu Y, Tang F, Shi Y, Ma L, Zhou T, Kaufmann W, Carey LA, Wu J, Hu Z.

NPJ Breast Cancer. 2018 Oct 29;4:35. doi: 10.1038/s41523-018-0088-0. eCollection 2018.

14.

Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance.

Knight TG, Deal AM, Dusetzina SB, Muss HB, Choi SK, Bensen JT, Williams GR.

J Oncol Pract. 2018 Oct 24:JOP1800120. doi: 10.1200/JOP.18.00120. [Epub ahead of print]

PMID:
30355027
15.

Associations of functional, psychosocial, medical, and socio-demographic factors with cognitive screening in chemotherapy naïve patients with breast cancer.

Nakamura ZM, Deal AM, Nyrop KA, Choi SK, Wood WA, Muss HB.

Psychooncology. 2019 Jan;28(1):167-173. doi: 10.1002/pon.4928. Epub 2018 Nov 8.

PMID:
30353629
16.

Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going.

Copeland AC, Anders CK.

Oncology (Williston Park). 2018 Oct 15;32(10):483-7.

17.

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy.

Rose TL, Chism DD, Alva AS, Deal AM, Maygarden SJ, Whang YE, Kardos J, Drier A, Basch E, Godley PA, Dunn MW, Kim WY, Milowsky MI.

Br J Cancer. 2018 Oct;119(7):801-807. doi: 10.1038/s41416-018-0229-0. Epub 2018 Oct 8.

PMID:
30293995
18.

Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.

Wheeler SB, Spencer J, Pinheiro LC, Murphy CC, Earp JA, Carey L, Olshan A, Tse CK, Bell ME, Weinberger M, Reeder-Hayes KE.

J Natl Cancer Inst. 2018 Sep 20. doi: 10.1093/jnci/djy136. [Epub ahead of print]

PMID:
30239824
19.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN.

World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20.

PMID:
30238401
20.

Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began.

Meisel JL, Venur VA, Gnant M, Carey L.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):78-86. doi: 10.1200/EDBK_201037. Review.

PMID:
30231395

Supplemental Content

Loading ...
Support Center